A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

NCT ID: NCT06016270

Last Updated: 2025-09-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-13
• Study Completion Date: 2025-08-25

Brief Summary

The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.

Detailed Description

The study will be conducted in 2 parts. Phase Ib will evaluate the safety of the combination of hSTC810 with a standard dose of paclitaxel using a 3+3 dose escalation design. Phase II will evaluate the efficacy of hSTC810 + paclitaxel combination therapy using a Simon 2-stage method.

Conditions

Extensive Stage Small Cell Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

hSTC810 400 mg + Paclitaxel

hSTC810 400 mg will be administered with a standard dose of paclitaxel

Group Type: EXPERIMENTAL

hSTC810 400 mg + Paclitaxel

Intervention Type: DRUG

hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion

Paclitaxel: 175 mg/m2 will be administered as an IV infusion

hSTC810 800 mg + Paclitaxel

hSTC810 800 mg will be administered with a standard dose of paclitaxel

Group Type: EXPERIMENTAL

hSTC810 800 mg + Paclitaxel

Intervention Type: DRUG

hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion

Interventions

hSTC810 400 mg + Paclitaxel

hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion

Paclitaxel: 175 mg/m2 will be administered as an IV infusion

Intervention Type: DRUG

hSTC810 800 mg + Paclitaxel

hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ability to understand and sign an informed consent form
• Male or female ≥ 18 years of age
• Histologically or cytologically confirmed SCLC
• R/R ES-SCLC on or after platinum-based chemotherapy for SCLC with documented disease progression
• At least 1 measurable lesion as defined by RECIST 1.1
• Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 or 1
• Life expectancy of at least 3 months
• Adequate organ function as described in the protocol
• For female or male patients with reproductive potential: Agree to use contraception throughout the study and at least 5 months after the last dose.

Exclusion Criteria

• Known active leptomeningeal disease (carcinomatous meningitis)
• Known active and uncontrolled central nervous system (CNS) metastases
• Treatment with immunotherapy, chemotherapy, targeted small molecule therapy, or any other investigational agent < 14 days prior to initiation of study treatment
• Treatment with radiation therapy < 14 days prior to initiation of study treatment
• Major surgery < 21 days prior to initiation of study treatment
• Received live vaccine < 30 days prior to initiation of study treatment, including intranasal influenza vaccine
• History of another primary malignancy with protocol-defined exceptions
• Active or history of autoimmune disease requiring systemic treatment
• Receiving high doses of steroids or other immunosuppressive medications
• Active hepatitis B or C infection
• Active or history of non-infectious pneumonitis requiring treatment with steroids
• Active uncontrolled viral, fungal, or bacterial infection including tuberculosis
• Pregnant or breastfeeding female patients
• History of severe hypersensitivity reaction to a monoclonal antibody treatment
• History of severe hypersensitivity reaction or ≥ Grade 3 adverse event (AE) to paclitaxel treatment
• History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to screening
• QT Corrected for Fridericia's method (QTcF) > 470 ms at screening
• Lack of resolution of any toxicity to max Grade 1 (except alopecia)
• Active or history of any condition, therapy, or lab abnormality that may interfere with the patient participation for the full duration of the study
• Known psychiatric or substance use disorder
• Positive Coronavirus disease 2019 (COVID-19) test at screening

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

STCube, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Tisch Cancer Institute at Mount Sinai

New York, New York, United States

MD Anderson Cancer Center

Houston, Texas, United States

Korea University Anam Hospital

Seoul, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

Seoul National University Bundang Hospital

Seoul, , South Korea

The Catholic University of Korea St. Vincent's Hospital

Suwon, , South Korea

Countries

United States; South Korea

Other Identifiers

STCUBE-002

Identifier Type: -

Identifier Source: org_study_id